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Minor depression is diagnosed when a patient suffers from 2 to 4 depressive symptoms
for at least 2 weeks. Though minor depression is a widespread phenomenon, its
pathophysiology has hardly been studied. To get a first insight into the pathophysiological
mechanisms underlying this disorder we assessed serum levels of biomarkers for
plasticity, glial and neuronal function: brain-derived neurotrophic factor (BDNF), S100B
and neuron specific enolase (NSE). 27 subjects with minor depressive episode and 82
healthy subjects over 60 years of age were selected from the database of the Leipzig
population-based study of civilization diseases (LIFE). Serum levels of BDNF, S100B
and NSE were compared between groups, and correlated with age, body-mass index
(BMI), and degree of white matter hyperintensities (score on Fazekas scale). S100B was
significantly increased in males with minor depression in comparison to healthy males,
whereas other biomarkers did not differ between groups (p = 0.10–0.66). NSE correlated
with Fazekas score in patients with minor depression (rs = 0.436, p = 0.048) and in the
whole sample (rs = 0.252, p = 0.019). S100B correlated with BMI (rs = 0.246, p = 0.031)
and with age in healthy subjects (rs = 0.345, p = 0.002). Increased S100B in males with
minor depression, without alterations in BDNF and NSE, supports the glial hypothesis of
depression. Correlation between white matter hyperintensities and NSE underscores the
vascular hypothesis of late life depression.
Keywords: minor depression, late life depression, S100B, BDNF, NSE, glia, white matter hyperintensities,
biomarker
INTRODUCTION
Minor depression is a widespread phenomenon in late life (Hegerl and Schoenknecht, 2009;
Polyakova et al., 2015). According to the fourth edition of the diagnostic statistical manual of mental
disorders (DSM-IV) a person suffering from two to four depressive symptoms for at least 2 weeks
has a minor depressive episode. For diagnosis of minor depressive disorder one additionally has
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to exclude a history of major depression (American Psychiatric
Association, 2000). In clinical practice patients with minor
depressive symptoms may represent an independent minor
depressive episode or a subsyndromal stage of major depression
(Park et al., 2010). Every fourth patient with minor depression
develops major depression within 2 years after diagnosis (Lyness
et al., 1999) and 13% of subjects with minor depression have
attempted suicide at least once (Eaton et al., 1995). With regard
to these data proper diagnosis and management of minor
depression might become an approach to prevent a more severe
depressive disorder.
Although plenty of studies have been conducted to elucidate
the etiology of major depression, the pathophysiology of minor
depression is still unknown. Possible research directions include
the glial, neurotrophic and vascular hypotheses of depression.
Alterations of peripheral biomarkers of brain structure and
function might shed light on the pathological changes in central
mechanisms. Brain derived neurotrophic factor (BDNF), S100B
and neuron specific enolase (NSE) are among the most studied
biomarkers in affective disorders, in particular major depressive
disorder (Schroeter et al., 2002; Hetzel et al., 2005; Andreazza
et al., 2007; Schroeter and Steiner, 2009; Kalia and Silva,
2015).
BDNF, associated with plasticity in the central and peripheral
nervous system, is decreased in serum in acute major depressive
episodes and restored in remission (Molendijk et al., 2014). The
glial marker protein S100B is elevated during major depressive
episodes and decreased following successful treatment (Schroeter
et al., 2013). Thus, fluctuations in serum levels of BDNF and
S100B seem to be state markers for major depression. This
is supported by powerful meta-analyses including a very high
number of subjects (Schroeter et al., 2008; Polyakova et al.,
2015). NSE is a marker for neuronal injury. In contrast to BDNF
and S100B, serum NSE levels seem to be stable in depression
suggesting mainly glial dysfunction (Schroeter et al., 2013).
However, a recent publication reported increased NSE levels in
cerebrospinal fluid (Schmidt et al., 2015), leaving more space for
discussion.
Due to clinical similarities with major depression, we expect
similar biomarker changes in minor depression. Since BDNF
levels do not correlate with depression severity (Molendijk
et al., 2011), decreased serum BDNF might also be observed
in minor depression. In this disorder it might reflect impaired
constitutive or activity-dependent BDNF expression, resulting in
impaired brain plasticity. Increased S100B in minor depression
may indicate early glial pathology that precedes specific neuronal
changes such as in major depression (Rajkowska, 2000).
Unaltered (comparing to healthy controls) NSE should confirm
that there is no neuronal damage in minor depression.
To further explore the etiology of minor depression we
analyzed serum levels of BDNF, S100B and NSE in subjects with
minor depression and healthy control subjects from the Leipzig
population-based study of civilization diseases (LIFE). Serum
levels of BDNF, S100B and NSE were considered as primary
outcomes. In analogy to major depression we hypothesized a
decrease of BDNF and an increase of S100B, without changes of
NSE in minor depression.
An association between late life minor depression and the
vascular hypothesis of depression (Taylor et al., 2013) was
investigated in explorative analyses by correlating white matter
hyperintensities to serum markers. In order to control for
confounding variables we correlated age and body mass index
(BMI) with serum markers. Correlation of serum markers with
clinical and imaging parameters, such as age, BMI and extent
of white matter hyperintensities were considered as secondary
outcomes.
MATERIALS AND METHODS
Participants
Twenty seven subjects 60 years and older satisfying the DSM-IV
criteria for minor depressive episode and eighty two healthy
control subjects were selected from the LIFE study. LIFE study
includes a representative sample from the Leipzig population
(Loeffler et al., 2015). All of the participants provided their
written informed consent in accordance with the Declaration
of Helsinki before participation in the study. The study was
approved by the ethics board of the Medical Faculty of the
University of Leipzig. At the moment of subjects’ selection the
LIFE study database included 1617 subjects over 60 years of
age. Every subject underwent structured psychiatric interview,
neuropsychological testing, clinical examination, blood sampling
and scanning with multimodal magnetic resonance imaging
(MRI).
Diagnostic Criteria and Laboratory
Procedures
Minor depressive episode according to DSM-IV criteria was
diagnosed based on the structured clinical interview for DSM-
IV axis I disorders (SCID). White matter hyperintensities were
rated by experienced neuroradiologists using the Fazekas scale
(Fazekas et al., 1987) in fast fluid-attenuated inversion recovery
(FLAIR) images.
Blood samples were collected from the subject’s cubital vein at
the first day of the study. The mean time between blood sampling
and psychiatric interview was 10.0 (4.3) days for subjects with
minor depression and 13.0 (9.0) for healthy subjects. All samples
were collected uniformly in the morning, following overnight
fasting. Serum was prepared using the standard operating
procedures. In brief, samples were left for 45 min for clotting,
followed by a centrifugation step (10 min, 2750 g, 15◦C). Samples
were then filled in straws (CryoBioSytems IMV, France) by
an automatic aliquoting system (DIVA, CryoBioSytems IMV,
France). After that serum samples were stored at −80◦C. To
minimize freeze-thaw cycles, samples were sorted in a cryogenic
work bench (temperatures below −100◦C) and automatically
stored in tanks with a coolable top frame in the gas phase of liquid
nitrogen (Askion, Germany; Loeffler et al., 2015).
S100B and NSE were measured with monoclonal 2-site
immunoluminometric assays performed on the fully mechanized
system LIAISON (Diasorin, Dietzenbach, Germany). The
detection limit for the assays was 0.02 µg/l and 0.04 µg/l
(described in detail elsewhere (Streitbuerger et al., 2012). BDNF
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was measured in serum with an ELISA manufactured by R&D
systems (Wiesbaden, Germany). The sensitivity of the assay was
20 ng/L leading to a measuring range of 62.5 until 4000 ng/L.
Interassay coefficients of variation were between 9.4 and 11.1%
formean BDNF concentrations between 362 and 2079 ng/L. Note
that serum samples were diluted 1:20 before measuring them
with the assay.
Statistical Analyses
Statistical analyses were performed using SPSS version 22
(IBM, Chicago, IL, USA). Complex assessment of the data
distributions were performed including visual assessment of the
histograms, skewness and kurtosis of the data, as well as by
Kolmogorov–Smirnoff and Shapiro-Wilk test. Since the protein
levels were non-normally distributed and different numbers of
subjects were included in patients’ and controls’ groups we
applied non-parametric Mann-Whitney U test for evaluation
of group differences. The differences in demographic factors
were assessed by independent t-test or by chi-square test. The
impact of sex differences and a history of depression were
assessed by subgroup analyses. The correlation analyses between
serum markers, clinical/imaging and demographic data were
performed by calculating Spearmen correlation coefficients. We
expected directed changes for BDNF and S100B in minor
depression in comparison with control subjects, therefore
one-tailed α-level for statistical significance was set at 0.05
for these biomarkers. For NSE and the correlation analyses
two-tailed α-level at 0.05 was chosen. The statistical power was
calculated using G-power 3.1.9.2. (Faul et al., 2009). Generally,
data are presented as means and standard deviations (SD). Dot
plots represent the distributions of the protein levels and their
medians.
RESULTS
The demographics, clinical and imaging data, and serum marker
levels of the patients and healthy control subjects are presented
in Table 1. Both cohorts were matched for age, education, BMI
and the extent of white matter hyperintensities as measured with
the Fazekas scale.
BDNF, S100B and NSE did not differ between patients in
minor depressive episode and healthy control subjects (Table 1).
Since the two groups differed with regard to sex, we conducted
additionally sex-specific analyses. Figure 1 illustrates results
with dot plots for the three serum marker proteins across the
whole groups, and specifically for each sex. When the analysis
was stratified by sex we observed significantly increased S100B
(p = 0.034) in males with minor depressive episode (0.092 µg/l
[0.012]) in comparison with healthy male controls (0.067 µg/l
[0.004]).
As depicted in the Figure 2, serum S100B levels were
significantly lower in healthy males (0.067 µg/l [0.004]) in
comparison with healthy females (0.115 µg/l [0.029]; p = 0.01),
whereas there was no sex difference in the minor depression
group (male: 0.091 µg/l [0.12]; female: 0.088 µg/l [0.011];
p = 0.53). Removal the abovementioned female outlier did not
affect the differences between healthy males and females for
S100B. BDNF and NSE did not differ neither between the groups
stratified by sex (males p = 0.13–0.95; females p = 0.40–0.42), nor
when male and female subjects were compared within the minor
depression subgroup (p = 0.10–0.98).
Similarly, presence of the history of major depression did
not affect the levels of BDNF, S100B or NSE in the minor
depression group (p = 0.10–0.50); neither in comparison with
healthy controls (p = 0.13–0.38; Figure 3).
As presented on Figure 1 one female control subject presented
with extremely high S100B value, above three SD of the group.
To control for the impact of this subject on the analysis of
S100B we performed an additional analysis of S100B excluding
this subject’s data. In this analysis we observed a trend,
p = 0.078, for increased S100B in the whole minor depression
group (0.088 µg/l [0.043]) in comparison with healthy controls
(0.074 µg/l [0.032]).
We observed a positive correlation between S100B and BMI
in the whole sample (rs = 0.204, p = 0.04), and in healthy subjects
(rs = 0.246, p = 0.03), and a positive correlation between S100B
TABLE 1 | Demographical, clinical/imaging data and serum markers in patients and healthy control subjects.
Whole group Males Females
MinD HC MinD HC MinD HC
Number (with a history of depression) 27 (14) 82 7 (3) 58 21 (11) 24
Age 71.2 (4.5) 70.0 (4.1) 71.4 (4.8) 70.3 (4.1) 71.1 (4.5) 69.6 (4.3)
Sex (male/female) 7/21∗∗∗ 51/31∗∗∗
Education (<12years/>12 years) 24/4 58/24 5/2 37/15 19/2 22/9
Fazekas score (0/1/2/3) 6/16/5/0 25/45/12/0 2/4/0/0 17/27/7/0∗ 4/12/5/0 8/18/5/0
BMI (kg/m2) 27.1 (4.9) 28.1 (4.6) 26.7 (2.1) 27.8 (3.7) 27.2 (5.7) 28.7 (5.9)
BDNF (µg/L) 25.8 (5.4) 25.2 (5.9) 29.6 (14.2) 24.7 (4.3) 26.1 (4.9) 26.1 (7.8)
NSE (µg/L) 11.8 (2.6) 11.9 (2.1) 11.9 (2.9) 11.7 (2.3) 11.7 (2.6) 12.2 (1.7)
S100B (µg/L) 0.088 (0.043) 0.086 (0.11) 0.088 (0.03)∗ 0.067 (0.03)∗† 0.088 (0.05) 0.12 (0.16)†
MinD, minor depression; HC, healthy controls; BMI, body-mass index; BDNF, brain derived neurotrophic factor; NSE, neuron specific enolase; †Significant difference
between males and females at p < 0.05; ∗Significant difference between minor depression and healthy controls group at p < 0.05; ∗∗∗Significant difference between
minor depression and healthy controls group at p < 0.001; Student’s t-test for age and body mass index, chi-square test for categorical data, Mann-Whitney U test for
BDNF, NSE, S100B.
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FIGURE 1 | Dot plot for the distribution of serum markers’ levels in subjects and healthy controls (first row), separately for males (second row), and
females (third row). Median levels of the serum markers are depicted with black horizontal lines. Note that the distribution of S100B in males is depicted on a
zoomed scale. MinD, minor depression; HC, healthy controls; BDNF, brain derived neurotrophic factor; NSE, neuron specific enolase.
and age in the whole sample (rs = 0.229, p = 0.02) and in healthy
control subjects (rs = 0.345, p = 0.002).
A significant positive correlation was found between age and
the degree of white matter hyperintensities as measured with the
Fazekas score both, in the whole sample (rs = 0.425, p < 0.001),
and in subgroups (minor depression: rs = 0.462, p = 0.04; healthy
controls: rs = 0.421, p < 0.001). With regard to serum markers,
Fazekas score correlated positively with NSE in the whole sample
(rs = 0.252, p = 0.02) and in patients with minor depression
(rs = 0.436, p = 0.048). In the healthy control sample the Fazekas
score correlated positively only with S100B (rs = 0.261, p = 0.04).
Finally, we examined whether our groups were large
enough to detect the predicted impact of minor depression
on serum BDNF and S100B. The statistical power calculations
using G-Power for Mann-Whitney tests were based on the
previous meta-analyses of BDNF and S100B alterations in major
depression (Schroeter et al., 2013; Polyakova et al., 2015). These
calculations lead to required sample sizes of n = 36 per group for
BDNF and n = 5 per group for S100B.
DISCUSSION
In this study, for the first time to our knowledge, we evaluated
serum levels of BDNF, S100B and NSE in subjects with minor
depressive episode. We found evidence for increased S100B
in males with minor depression without any alterations of
NSE, which was in agreement with our hypotheses. BDNF was
unchanged, although we expected a decrease in analogy to
major depression. In assessment of the secondary outcomes we
observed a positive correlation between NSE and Fazekas score
in minor depression and in the whole sample. S100B correlated
positively with age and BMI in the whole sample and in healthy
controls.
Our hypotheses were initially built on data derived from
major depression studies. In minor depression we didn’t detect
the hypothesized difference for BDNF. One explanation of such
a negative finding might be that neurotrophic functions are
not impaired at the subthreshold level of depression. Then the
substantial differences in the pathophysiology of these disorders
arise. Nevertheless, one might also argue that the sample size
was too low. The calculation of the required sample size using
G-Power for BDNF indeed showed that our minor depressive
group might have been underpowered (27 subjects instead of the
36 required). In this study we reached only 75% of statistical
power. To solve the power issue future studies should involve
larger sample size.
For S100B the sample size was obviously large enough to
detect the expected group effects (27 subjects instead of five
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FIGURE 2 | Dot plot for the distribution of serum markers’ levels in healthy males and females (first row), and males and females with minor
depression (third row). Median levels of the serum markers are depicted with black horizontal lines. Note that the outlier from the healthy females group is not
depicted on the S100B plot. MinD, minor depression; HC, healthy controls; BDNF, brain derived neurotrophic factor; NSE, neuron specific enolase.
required). Indeed, we observed a trend for increased S100B in
the whole minor depression group and significantly increased
S100B in males with minor depression in comparison with
control subjects. Though we did not rule out potential non-
brain sources of S100B in our study, this finding points to the
similarities between major and minor depression. Moreover, the
fact that differences in S100B are less prominent than in major
depression suggests that clinical presentation mirrors to some
extend molecular changes.
The findings we describe are based on the concept that
serum S100B changes are related to alterations in the brain.
However, S100B, as well as BDNF, and NSE might originate
from non-brain sources. For instance, various subtypes of
leukocytes can secrete S100B (Miki et al., 2013; Fujiya et al.,
2014; Moutsatsou et al., 2014). Thrombocytes are the largest
source for serum BDNF (Fujimura et al., 2002), adipocytes
produce both S100B and BDNF (Fujiya et al., 2014; Huang
et al., 2014), finally NSE may originate from damaged peripheral
nerves (Li et al., 2013). Because we did not assume relevant
biases related to these potentially confounding sources in minor
depression, we did not control for potential non-brain sources of
the serum markers in our study. Note that we compared subjects
with minor depression to matched healthy control subjects and
considered, therefore, differences and not absolute values of
FIGURE 3 | Dot plot for the distribution of serum markers’ levels in subjects with minor depression with or without a history of depression. Median
levels of the serum markers are depicted with black horizontal lines. MinD, minor depression, HC, healthy controls; BDNF, brain derived neurotrophic factor; NSE,
neuron specific enolase.
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S100B. Moreover, changes of S100B in leukocytes have been
shown only in bipolar disorder (Moutsatsou et al., 2014), whereas
for unipolar depression, which is more relevant for our data, no
studies are available in the literature so far. Future studies might
transcend these limitations by including larger and more strictly
selected cohorts and controlling for non-brain sources of these
markers.
The concept of leakage from the brain obviously has its
limitations. S100B, as well as BDNF, and NSE might originate
from non-brain sources. Various subtypes of leucocytes can
secrete S100B (Miki et al., 2013; Fujiya et al., 2014; Moutsatsou
et al., 2014), thrombocytes are the largest source for serum
BDNF (Fujimura et al., 2002), adipocytes produce both S100B
and BDNF (Fujiya et al., 2014; Huang et al., 2014), finally NSE
originate from damaged peripheral nerves (Li et al., 2013).
Interestingly, S100B was not different between males and
females with minor depression, rather it differed between healthy
males and females. This finding is in line with previous studies
showing no sex differences in major depression (Arolt et al.,
2002; Hetzel et al., 2005), but contradicts another one showing
increased S100B in females with major depression (Yang et al.,
2008). The differences between our and the former study might
be attributed to the differences in the studied samples with regard
to disease severity and age. Further studies are in agreement
with our finding for healthy subjects by showing higher S100B
in healthy female than male adults (Streitbuerger et al., 2012) and
children (Gazzolo et al., 2003). Overall, the literature on effects of
gender on S100B did not reach consensus so far. Whether gender
differences in S100B reflect the differences in susceptibility to
disease and whether S100B is a gender-specific marker of minor
depression needs more systematic assessment.
S100B, as an index for glial alterations, is modified by age in
major depression (Schroeter et al., 2011). In minor depression
we did not find a correlation between S100B and age. Instead,
S100B correlated positively with age in healthy controls. This
finding is in line with cerebrospinal fluid studies (van Engelen
et al., 1992; Nygaard et al., 1997), but contradicts later serum
studies (Wiesmann et al., 1998; Portela et al., 2002). One
potential reason for these differences is again the different disease
severity. According to Rajkowska’s observations development of
depressive disorder starts with glial alterations and progresses
with age (Rajkowska, 2000). If late life minor depression is a
subtle manifestation of major disorder, absence of correlation
between S100B and age in minor depression might add to
Raikowska’s hypothesis.
A weak positive correlation between S100B and BMI was
not surprising. S100B is secreted by adipocytes and is involved
in the pathogenesis of obesity as shown in vitro (Fujiya et al.,
2014) and in vivo (Buckman et al., 2014). Positive correlation of
serum S100B with BMI was previously reported in a combined
sample of cognitively intact lean and obese subjects (Steiner et al.,
2010a) and in subjects with schizophrenia (Steiner et al., 2010b).
In our study the positive correlation in the whole sample was
likely driven by the healthy subgroup, with no such association
in minor depressive episode. As correlations between S100B
and age/BMI were detected only in healthy subjects but not in
the minor depression group, and both cohorts were matched
regarding mean age and BMI, we assume that age and BMI did
not drive the S100B effects in minor depression.
The finding of positive correlation between S100B and white
matter hyperintensities in healthy subjects is in agreement
with a study by Streitbuerger et al. (2012). These authors
reported an association between serum S100B and the diffusion
tensor imaging parameters fractional anisotropy and radial
diffusivity in white matter tracts in healthy females. From the
biological point of view increased secretion of S100B might
reflect neuroinflammation that accompanies neuronal damage
(Kabadi et al., 2015).
We detected also a positive correlation between serum NSE
and Fazekas score in the whole sample and in the minor
depression subgroup. NSE, a peripheral marker of neuronal
damage, might be either of central (Cheng et al., 2014)
or peripheral origin (Li et al., 2013). In major depression
a central origin is suggested by the correlation with white
matter hyperintensities. Finally, the extent of white matter
hyperintensities correlated with age in both cohorts, healthy and
minor depressive subjects, which is in line with the literature
(Nyquist et al., 2015). In combination with the correlation
between white matter hyperintensities and the neuronal injury
marker NSE in minor depression, our data might support the
vascular hypothesis of late life depression (Taylor et al., 2013;
Taylor, 2014).
Limitations
As already discussed our study was limited by a relatively small
sample size, which might have hampered, in particular, the
detection of BDNF effects. Another limitation might be the
inclusion of patients having a history of depression. Thus, not all
patients could be qualified as having minor depressive disorder.
We addressed this issue in the subgroup analysis and found
that inclusion of the subjects with a history of depression did
not affect our results. In fact, such a sample mirrors a real life
situation when psychiatrists need to make a clinical judgement
and select a treatment strategy. Note, moreover, that our subjects
were chosen from a representative population study.
The findings we describe are based on the concept that
serum S100B changes are related to alterations in the brain.
However, S100B, as well as BDNF, and NSE might originate
from non-brain sources. For instance, various subtypes of
leukocytes can secrete S100B (Miki et al., 2013; Fujiya
et al., 2014; Moutsatsou et al., 2014). Thrombocytes are
the largest source for serum BDNF (Fujimura et al., 2002),
adipocytes produce both S100B and BDNF (Fujiya et al.,
2014; Huang et al., 2014), finally NSE may originate from
damaged peripheral nerves (Li et al., 2013). Because we
did not assume relevant biases related to these potentially
confounding sources in minor depression, we did not control
for potential non-brain sources of the serum markers in our
study. Note that we compared subjects with minor depression
to matched healthy control subjects and considered, therefore,
differences and not absolute values of S100B. Moreover,
changes of S100B in leukocytes have been shown only in
bipolar disorder (Moutsatsou et al., 2014), whereas for unipolar
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depression, which is more relevant for our data, no studies
are available in the literature so far. Future studies might
transcend these limitations by including larger and more strictly
selected cohorts and controlling for non-brain sources of these
markers.
CONCLUSION
In this study we made a first attempt to assess serum levels
of BDNF, S100B, and NSE in minor depression. We found
evidence for increased glial marker S100B in males with minor
depression and a similar trend in the whole minor depressive
group, but no significant evidence of BDNF and NSE alterations.
The positive correlation of NSE with Fazekas score as a measure
for white matter hyperintensities in minor depression supports
the vascular hypothesis of late life depression.
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